|
Zydus Lifesciences has reported a growth of over 38 per cent in net profit at Rs. 1,258.6 crore during the second quarter ended September 30, 2025, as compared to Rs. 911.2 crore registered in the same period of previous fiscal year.
The total revenue from operations grew almost 17 per cent to Rs. 6,123.2 crore during the quarter, as against Rs. 5,237 crore on a year-over-year (YoY) basis. EBITDA for the quarter was Rs. 2,015.8 crore, up 38 per cent YoY. EBITDA margin for the quarter stood at 32.9 per cent, which is an improvement of 500 bps on a YoY basis, said the company.
The company announced plans to raise funds to the tune of around Rs. 5,000 crore by issuing eligible securities by way of Qualified Institutions Placement (QIP), rights issue, preferential allotment, private placement, or any combination of these routes or other permitted methods.
Research & development (R&D) investments for the quarter stood at Rs. 482 crore, which is 7.9 per cent of revenues. During the quarter, the capex for organic growth for the company was at Rs. 491.1 crore.
Dr. Sharvil Patel, managing director, Zydus Lifesciences Ltd said, "Our strong performance this quarter reaffirms the power of our diversified business model and our execution capabilities across geographies and verticals."
"We delivered robust revenue growth and industry-leading profitability, aided by consistent outperformance in our US and India formulations businesses, sustained high growth in International Markets as well as strategic acquisitions in Wellness and MedTech," he added.
US formulations sales of the company grew almost 13.5% to Rs. 2,743.7 crore during the quarter and accounts to almost 45 per cent of the total business, while India formulations business grew 8.4 per cent at Rs. 1,593.1 crore with 26 per cent share of the overall business. International formulations business reported a growth of 39.4 per cent at Rs. 751.3 crore, while consumer wellness business grew 30.7 per cent growth at Rs. 637.4 crore during the quarter.
API business grew 23.3 per cent at Rs. 147.2 crore, as compared to Rs. 119.4 crore during the quarter. MedTech, a business which it entered into through strategic acquisition, accounted for almost three percent of the business with Rs. 153.2 crore sales during the period.
During the first six months of the fiscal year, the net profit grew around 17 per cent to Rs. 2,725.4 crore, as against Rs. 2,331.1 crore profit reported in the same period a year ago. Total revenue from operations reported a growth of 11 per cent at Rs. 12,696.9 crore from Rs. 11,444.5 crore registered during April to September, 2024.
EBITDA was Rs. 4,104.3 crore, up 16 per cent YoY. EBITDA margin stood at 32.3 per cent, which is an improvement of 130 bps over the previous year. Capex (organic) for the half year was Rs. 893.1 crore.
It may be noted that the company has successfully completed acquisition of UK based Comfort Click Limited including its three subsidiaries located in Ireland, US and India (CCL or Comfort Click). The acquisition marks Zydus Wellness’ first overseas acquisition and its entry into the vitamins, minerals and supplements (VMS) segment.
|